Keeping Track: US FDA Approves Novartis’ Scemblix; Lilly Submits Tirzepatide, Withdraws Tanezumab

 
• By Bridget Silverman
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers